TITLE

Interim results showed AV-951 active against renal cell carcinoma

AUTHOR(S)
Harris, Jason
PUB. DATE
April 2009
SOURCE
Hem/Onc Today;4/10/2009, Vol. 10 Issue 7, p16
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses a study which showed that the novel oral vascular endothelial growth factor (VEGF) kinase inhibitor AV-951 had a safety profile similar to that expected of a selective VEGF inhibitor and minimized the adverse events for patients with renal cell carcinoma.
ACCESSION #
37292859

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics